Head and neck Cancer an evolving treatment paradigm

Cancer

Volumn 113, Issue 7, 2008, Pages 1911-1932

  Cognetti, David M ^a,d   Weber, Randal S ^b   Lai, Stephen Y ^a,b,c,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combined modality therapy; Concurrent chemotherapy; Head and neck Cancer; Head and neck squamous cell carcinoma (HNSCC); Head and neck surgery; Neck dissection; Radiation therapy

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINATE CALCIUM; IMATINIB; METHOTREXATE; MITOMYCIN C; PANITUMUMAB; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODE EXCISION; NECK;

EID: 53949104217     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23654     Document Type: Review

References (227)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, Murray T, Xu I, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Ries LAG, Melbert D, Krapcho M, et al. E. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Available from: http://seer.Cancer.gov/ csr/1975_2004/. Accessed on August 12, 2008.
4. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer. 2005;103:1843-1849.
5. Levin M. Some epidemiological features of Cancer. Cancer. 1948;1:489-497.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963-968.
7. The Surgeon General's Advisory Committee on Smoking and Health. Smoking and Health: Report of the Advisory Committee to the Surgeon General of Public Health Service. Public Health Service Publication No. 1103. Washington, DC: Department of Health Education, and Welfare, Public Health Service; 1964.
8. Watson WL, Conte AJ. Smoking and lung Cancer. Cancer. 1954;7:245-249.
9. Samji HA, Jackler RK. "Not one single case of throat irritation": misuse of the image of the otolaryngologist in cigarette advertising. Laryngoscope. 2008;118:415-427.
10. Hoffmann D, Wynder EL. A study of tobacco carcinogenesis. XI. Tumor initiators, tumor accelerators, and tumor promoting activity of condensate fractions. Cancer. 1971;27:848-864.
11. Wynder EL, Gottlieb S, Wright G. A study of tobacco carcinogenesis. IV Different tobacco types. Cancer. 1957; 10:1206-1209.
12. Wynder EL, Hoffmann D. A study of tobacco carcinogenesis. VII. The role of higher polycyclic hydrocarbons. Cancer. 1959;12:1079-1086.
13. Wynder EL, Hoffmann D. A study of tobacco carcinogenesis. VIII. The role of the acidic fractions as promoters. Cancer. 1961;14:1306-1315.
14. Wynder EL, Hoffmann D. A study of tobacco carcinogenesis. X. Tumor promoting activity. Cancer. 1969;24:289-301.
15. Wynder EL, Kopf P, Ziegler H. A study of tobacco carcinogenesis. II. Dose-response studies. Cancer. 1957;10:1193-1200.
16. Wynder EL, Mann J. A study of tobacco carcinogenesis. III. Filtered cigarettes. Cancer. 1957;10:1201-1205.
17. Wynder EL, Taguchi KT, Baden V, Hoffmann D. Tobacco carcinogenesis. IX. Effect of cigarette smoke on respiratory tract of mice after passive inhalation. Cancer. 1968;21:134-153.
18. Wynder EL, Wright G. A study of tobacco carcinogenesis. 1. The primary fractions. Cancer. 1957;10:255-271.
19. Wynder EL, Wright G, Lam J. A study of tobacco carcinogenesis. V The role of pyrolysis. Cancer. 1958;11:1140-1148.
20. Wynder EL, Wright GF, Lam J. A study of tobacco carcinogenesis. VI. The role of precursors. Cancer. 1959;12:1073-1078.
21. Wynder EL, Bross IJ. A study of etiologjcal factors in Cancer of the esophagus. Cancer. 1961;14:389-413.
22. Wynder EL, Bross IJ, Day E. A study of environmental factors in Cancer of the larynx. Cancer. 1956;9:86-110.
23. Wynder EL, Bross IJ, Feldman RM. A study of the etiological factors in Cancer of the mouth. Cancer. 1957;10:1300-1323.
24. Wynder EL, Covey LS, Mabuchi K, Mushinski M. Environmental factors in Cancer of the larynx: a second look. Cancer. 1976;38:1591-1601.
25. Vogler WR, Lloyd JW, Milmore BK. A retrospective study of etiological factors in Cancer of the mouth, pharynx, and larynx. Cancer. 1962;15:246-258.
26. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal Cancer. Cancer Res. 1988;48:3282-3287.
27. Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking, and Cancer of the oral cavity and oropharynx among US veterans. Cancer. 1993;72:1369-1375.
28. Muscat JE, Wynder EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal Cancer. Cancer. 1992;69:2244-2251.
29. Shindoh M, Chiba I, Yasuda M, et al. Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Cancer. 1995;76:1513-1521.
30. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-475.
31. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89:213-228.
32. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck Cancer: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31:259-266.
33. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck Cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997;79:595-604.
34. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125-1131.
35. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal Cancer. N Engl J Med. 2007;356:1944-1956.
36. Schwartz SM, Daling JR, Doody DR, et al. Oral Cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst. 1998;90:1626-1636.
37. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24:5630-5636.
38. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92:805-813.
39. Martin H, Del Valle B, Ehrlich H, Cahan WG. Neck dissection. Cancer. 1951;4:441-499.
40. Crile G. Excision of Cancer of the head and neck. With special reference to the plan of dissection based on 1 hundred and thirty-2 operations. JAMA. 1906;47:1780-1786.
41. Ferlito A, Rinaldo A, Silver CE, et al. Neck dissection: then and now. Auris Nasus Larynx. 2006;33:365-374.
42. Martin H. The case for prophylactic neck dissection. Cancer. 1951;4:92-97.
43. Myers EN, Gastman BR. Neck dissection: an operation in evolution: Hayes Martin lecture. Arch Otolaryngol Head Neck Surg. 2003;129:14-25.
44. Suarez O. El problema de las metastasis linfaticas y alejadas del Cancer de laringe e hypofaringe. Rev Otorrinolaringol. 1963;23:83-99.
45. Bocca E. Supraglottic laryngectomy and functional neck dissection. J Laryngol Otol. 1966;80:831-838.
46. Bocca E, Pignataro O, Sasaki CT. Functional neck dissection. A description of operative technique. Arch Otolaryngol. 1980;106:524-527.
47. Bocca E, Pignataro O, Oldini C, Cappa C. Functional neck dissection: an evaluation and review of 843 cases. Laryngoscope. 1984;94:942-945.
48. Frazell EL, Lucas JC Jr. Cancer of the tongue. Report of the management of 1554 patients. Cancer. 1962; 15:1085-1099.
49. Vandenbrouck C, Sancho-Garnier H, Chassagne D, Saravane D, Cachin Y, Micheau C. Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. Cancer. 1980;46:386-390.
50. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1972;29:1446-1449.
51. Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg. 1990;160:405-409.
52. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990;66:109-113.
53. Johnson JT, Barnes EL, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol. 1981;107:725-729.
54. Johnson JT, Myers EN, Bedetti CD, Barnes EL, Schramm VL Jr, Thearle PB. Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. Arch Otolaryngol. 1985;111:534-537.
55. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci. 1982;7:185-192.
56. Snyderman NL, Johnson JT, Schramm VL Jr, Myers EN, Bedetti CD, Thearle P. Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer. 1985; 56:1597-1599.
57. Byers RM. Modified neck dissection. A study of 967 cases from 1970 to 1980. Am J Surg. 1985;150:414-421.
58. Johnson JT, Wagner RL, Myers EN. A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Cancer. 1996;77:181-185.
59. Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified neck dissection. Head Neck Surg. 1988;10:160-167.
60. Pitman KT, Johnson JT, Myers EN. Effectiveness of selective neck dissection for management of the clinically negative neck. Arch Otolaryngol Head Neck Surg. 1997;123:917-922.
61. Chepeha DB, Hoff PT, Taylor RJ, Bradford CR, Teknos TN, Esclamado RM. Selective neck dissection for the treatment of neck metastasis from squamous cell carcinoma of the head and neck. Laryngoscope. 2002;112:434-438.
62. Pellitteri PK, Robbins KT, Neuman T. Expanded application of selective neck dissection with regard to nodal status. Head Neck. 1997;19:260-265.
63. Simental AA Jr, Duvvuri U, Johnson JT, Myers EN. Selective neck dissection in patients with upper aerodigestive tract Cancer with clinically positive nodal disease. Ann Otol Rhinol Laryngol. 2006;115:846-849.
64. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a "sentinel node" in Cancer of the parotid. Cancer. 1960;13:77-78.
65. Shoaib T, Soutar DS, MacDonald DG, et al. The accuracy of head and neck carcinoma sentinel lymph node biopsy in the clinically NO neck. Cancer. 2001;91:2077-2083.
66. Cote V, Kost K, Payne RJ, Hier MP. Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck: where we stand now, and where we are going. J Otolaryngol. 2007;36:344-349.
67. Lombardi CP, Raffaelli M, Princi P, De Crea C, Bellantone R. Minimally invasive video-assisted functional lateral neck dissection for metastatic papillary thyroid carcinoma. Am J Surg. 2007;193:114-118.
68. Terris DJ, Monfared A, Thomas A, Kambham N, Saenz Y. Endoscopic selective neck dissection in a porcine model. Arch Otolaryngol Head Neck Surg. 2003;129:613-617.
69. Malloy KM, Cognetti DM, Wildemore BM, et al. Feasibility of endoscopic sentinel node biopsy in the porcine neck. Otolaryngol Head Neck Surg. 2007;136:806-810.
70. Pitman KT, Sisk JD. Endoscopic sentinel lymph node biopsy in a porcine model. Laryngoscope. 2006;116:804-808.
71. Morrison LF. Carcinoma of the larynx. I. Carcinoma of the laryngopharynx. Laryngoscope. 1952;62:53-60.
72. Pollack RS. Laryngectomy and radical neck dissection. Cancer. 1955;8:1177-1184.
73. Martin H. The incidence of total and partial laryngectomy, 1947 and 1952. Cancer. 1955;8:1122-1125.
74. Pressman JJ, Simon MB, Monell CM. Anatomic studies related to the dissemination of Cancer of the larynx. Cancer. 1961;14:1131-1138.
75. Alonso J. Conservative surgery of the larynx. Trans Am Acad Ophthalmol Otolaryngol. 1947;51:633-642.
76. Majer EH, Rieder W. [Technic of laryngectomy permitting the conservation of respiratory permeability (cricohyoidopexy).] Ann Otolaryngol Chir Cervicofac. 1959;76:677-681.
77. Weinstein GS, Laccourreye O, Brasnu D, Laccourreye H. Organ Preservation Surgery for Laryngeal Cancer. San Diego, Calif: Singular Publishing Group; 2000.
78. MacComb WS. Cancer of the larynx. Cancer. 1966;19:149-156.
79. Ambrosch P. The role of laser microsurgery in the treatment of laryngeal Cancer. Curr Opin Otolaryngol Head Neck Surg. 2007;15:82-88.
80. Genden EM, Ferlito A, Silver CE, et al. Evolution of the management of laryngeal Cancer. Oral Oncol. 2007;43:431-439.
81. Solares CA, Strome M. Transoral robot-assisted CO2 laser supraglottic laryngectomy: experimental and clinical data. Laryngoscope. 2007;117:817-820.
82. Weinstein GS, O'Malley BW Jr, Snyder W, Hockstein NG. Transoral robotic surgery: supraglottic partial laryngectomy. Ann Otol Rhinol Laryngol. 2007;116:19-23.
83. Conley JJ. Free skin grafting in the sinus, oral, and pharyngeal areas in radical surgery of the head and neck. Cancer. 1954;7:444-454.
84. Edgerton MT Jr. Replacement of lining to oral cavity following surgery. Cancer. 1951;4:110-119.
85. Conway H, Murray JE. Indications for reconstruction at the time of surgical excision of Cancer of the oral cavity. Cancer. 1953;6:46-56.
86. Walsh TS Jr. Buried metallic prosthesis for mandibular defects. Cancer. 1954;7:1002-1009.
87. Wilkins SA Jr. Immediate reconstruction of the cervical esophagus: a new method. Cancer. 1955;8:1189-1197.
88. Harrold CC Jr. The artificial pharyngeal pouch: another alternative in reconstruction after laryngectomy. Cancer. 1957;10:928-932.
89. Bakamjian VY. A two-stage method for pharyngoesophageal reconstruction with a primary pectoral skin flap. Plast Reconstr Surg. 1965;36:173-184.
90. McCraw JB, Dibbell DG, Carraway JH. Clinical definition of independent myocutaneous vascular territories. Plast Reconstr Surg. 1977;60:341-352.
91. Ariyan S. The pectoralis major myocutaneous flap. A versatile flap for reconstruction in the head and neck. Plast Reconstr Surg. 1979;63:73-81.
92. Soutar DS, Scheker LR, Tanner NS, McGregor IA. The radial forearm flap: a versatile method for intra-oral reconstruction. Br J Plast Surg. 1983;36:1-8.
93. Yang G. Forearm free skin flap transplantation. Natl Med J China. 1981;61:139-141.
94. Gilbert A. Free transfer of the fibular shaft. Int J Microsurg. 1979;1:100-105.
95. Urken ML. Composite free flaps in oromandibular reconstruction. Review of the literature. Arch Otolaryngol Head Neck Surg. 1991;117:724-732.
96. Smith RB, Sniezek JC, Weed DT, Wax MK. Utilization of free tissue transfer in head and neck surgery. Otolaryngol Head Neck Surg. 2007;137:182-191.
97. Snyderman CH, Carrau RL, Kassam AB, et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. J Surg Oncol. 2008;97:658-664.
98. Mehta RP, Cueva RA, Brown JD, et al. What's new in skull base medicine and surgery? Skull Base Committee Report. Otolaryngol Head Neck Surg. 2006;135:620-630.
99. Lai S, Walvekar R, Ferris R. Minimally invasive videoassisted thyroidectomy: expanded indications and oncologic completeness. Head Neck. In press.
100. Miccoli P, Berti P, Materazzi G, Donatini G. Minimally invasive video assisted parathyroidectomy (MIVAP). Eur J Surg Oncol. 2003;29:188-190.
101. Miccoli P, Materazzi G. Minimally invasive, video-assisted thyroidectomy (MIVAT). Surg Clin North Am. 2004;84:735-741.
102. Mead PH. Surgery or radiotherapy for tonsil Cancer? Cancer. 1963;16:195-198.
103. Langlands AO. Radiation therapy in the treatment of Cancer: the past, the present, and the future. Aust N Z J Surg. 1982;52:331-335.
104. Montana GS, Hellman S, Von Essen CF, Kligerman MM. Carcinoma of the tongue and floor of the mouth. Results of radical radiotherapy. Cancer. 1969;23:1284-1289.
105. Perez CA, Holtz S, Ogura JH, Dedo HH, Powers WE. Radiation therapy of early carcinoma of the true vocal cords. Cancer. 1968;21:764-771.
106. Kaplan MJ, Johns ME, Clark DA, Cantrell RW. Glottic carcinoma. The roles of surgery and irradiation. Cancer. 1984;53:2641-2648.
107. Fletcher GH, Jessee RH. The place of irradiation in the management of the primary lesion in head and neck cancers. Cancer. 1977;39(2 suppl):862-867.
108. Fletcher GH. Elective irradiation of subclinical disease in cancers of the head and neck. Cancer. 1972;29:1450-1454.
109. Jesse RH, Fletcher GH. Treatment of the neck in patients with squamous cell carcinoma of the head and neck. Cancer. 1977;39(2 suppl):868-872.
110. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol. 2006;29:290-297.
111. Nakamura K, Shioyama Y, Kawashima M, et al. Multiinstitutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:1045-1050.
112. Vikram B, Farr HW. Adjuvant radiation therapy in locally advanced head and neck Cancer. CA Cancer J Clin. 1983;33:134-138.
113. Strong EW, Henschke UK, Nickson JJ, Frazell EL, Tollefsen HR, Hilaris BS. Preoperative x-ray therapy as an adjunct to radical neck dissection. Cancer. 1966;19:1509-1516.
114. Fu KK, Cooper JS, Marcial VA, et al. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck Cancer. Int J Radiat Oncol Biol Phys. 1996;35:425-438.
115. Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck Cancer: final report of Study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 1987;10:19-30.
116. Vandenbrouck C, Sancho H, Le Fur R, Richard JM, Cachin Y. Results of a randomized clinical trial of preoperative irradiation versus postoperative in treatment of tumors of the hypopharynx. Cancer. 1977;39:1445-1449.
117. Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer. 2008;112:535-543.
118. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck Cancer. N Engl J Med. 2004;350:1945-1952.
119. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
120. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck Cancer. G4A Cancer J Clin. 2008;58:32-53.
121. Kasperts N, Slotman BJ, Leemans CR, de Bree R, Doornaert P, Langendijk JA. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer. 2006;106:1536-1547.
122. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:281-288.
123. Harrison LB. Applications of brachytherapy in head and neck Cancer. Semin Surg Oncol. 1997;13:177-184.
124. Hepel JT, Syed AM, Puthawala A, Sharma A, Frankel P. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck Cancer. Int J Radiat Oncol Biol Phys. 2005; 62:1444-1450.
125. Puthawala A, Nisar Syed AM, Gamie S, Chen YJ, Londrc A, Nixon V. Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. Int J Radiat Oncol Biol Phys. 2001;51:354-362.
126. Kupferman ME, Morrison WH, Santillan AA, et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer. 2007;109:2052-2057.
127. Most MD, Allori AC, Hu K, et al. Feasibility of flap reconstruction in conjunction with intraoperative radiation therapy for advanced and recurrent head and neck Cancer. Laryngoscope. 2008;118:69-74.
128. Withers HR. Biologic basis for altered fractionation schemes. Cancer. 1985;55(9 suppl):2086-2095.
129. Million RR, Parsons JT, Cassisi NJ. Twice-a-day irradiation technique for squamous cell carcinomas of the head and neck. Cancer. 1985;55(9 suppl):2096-2099.
130. Wang CC, Blitzer PH, Suit HD. Twice-a-day radiation therapy for Cancer of the head and neck. Cancer. 1985;55(9 suppl):2100-2104.
131. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck Cancer. J Clin Oncol. 2007;25:4118-4126.
132. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-146.
133. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck Cancer: a meta-analysis. Lancet. 2006;368:843-854.
134. Sanguineti G, Richetti A, Bignardi M, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck Cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys. 2005;61:762-771.
135. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck Cancer: promises and pitfalls. J Clin Oncol. 2006; 24:2618-2623.
136. Lee N, Puri DR, Blanco Al, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck. 2007;29:387-400.
137. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck. 2005;27:478-487.
138. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the US, 2004. Cancer. 2005;104:1296-1303.
139. Mell LK, Roeske JC, Mundt AJ. A survey of intensitymodulated radiation therapy use in the United States. Cancer. 2003;98:204-211.
140. Kaplan ID, Adler JR, Hicks WL Jr, Fee WE, Goffinet DR. Radiosurgery for palliation of base of skull recurrences from head and neck cancers. Cancer. 1992;70:1980-1984.
141. Ryu S, Khan M, Yin FF, et al. Image-guided radiosurgery of head and neck cancers. Otolaryngol Head Neck Surg. 2004;130:690-697.
142. Voynov G, Heron DE, Burton S, et al. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma Technol Cancer Res Treat. 2006;5:529-535.
143. Watne AL. Treatment alternatives. Head and neck cancers. Cancer. 1984;54(11 suppl):2673-2681.
144. Weaver Z 3rd, Thomas CG Jr. Further studies on topical chemotherapy in experimentally implanted Cancer. Cancer. 1962;15:584-590.
145. Burke E, Sako K. Cancer cells in wound washings in head and neck surgery. Cancer. 1960;13:772-774.
146. Smith RR, Thomas LB, Hilberg AW. Cancer cell contamination of operative wounds. Cancer. 1958;11:53-62.
147. Sullivan RD, Miller E, Sikes MR Antimetabolite-metabolite combination Cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human Cancer. Cancer. 1959;12:1248-1262.
148. Rogers LS. Cancer chemotherapy by continuous intra-arterial infusion. Experience of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Infusion Study Group. Cancer. 1964;17:1365-1380.
149. Warren SE, Van Prohaska J. An apparatus for intraarterial chemotherapy of Cancer. Cancer. 1963;16:564-566.
150. Feder RJ, Acquarelli MJ, Gordon HE. Complications inherent in continuous intra-arterial chemotherapy of head and neck carcinoma. Cancer. 1964;17:1385-1390.
151. Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck Cancer. J Clin Oncol. 2006;24:2629-2635.
152. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck Cancer. J Clin Oncol. 2004;22:1743-1752.
153. Gollin FF, Johnson RO. Preirradiation 5-fluorouracil infusion in advanced head and neck carcinomas. Cancer. 1971;27:768-770.
154. Ensley J, Crissman J, Kish J, et al. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer. 1986;57:711-717.
155. Hong WK, Shapshay SM, Bhutani R, et al. Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. Cancer. 1979;44:19-25.
156. Leitner SP, Bosl GJ, Strong EW, et al. A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck Cancer. Cancer. 1986;58:1014-1017.
157. Milazzo J, Mohit-Tabatabai MA, Hill GJ, et al. Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx. Cancer. 1985;56:1014-1017.
158. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck Cancer after 3-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985;55:1123-1128.
159. Schuller DE, Wilson HE, Smith RE, Batley F, James AD. Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer. 1983;51:15-19.
160. Vogl SE, Lerner H, Kaplan BH, Camacho F, Cinberg J, Schoenfeld D. Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous Cancer of the head and neck. Cancer. 1982;50:6-9.
161. [No authors listed] Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer. 1987;60:301-311.
162. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck Cancer: final report of the Southwest Oncology Group. Laryngoscope. 1988;98:1205-1211.
163. [No authors listed] Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal Cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685-1690.
164. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus Cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase HI trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88:890-899.
165. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal Cancer. N Engl J Med. 2003;349:2091-2098.
166. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group Trial 91-11. Arch Otolaryngol Head Neck Surg. 2003;129:44-49.
167. Argiris A. Induction chemotherapy for head and neck Cancer: will history repeat itself? J Natl Compr Canc Netw. 2005;3:393-403.
168. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck Cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179-1186.
169. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
170. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase HI study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck Cancer. J Clin Oncol. 2005;23:8636-8645.
171. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck Cancer. N Engl J Med. 2007;357:1705-1715.
172. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck Cancer. N Engl J Med. 2007;357:1695-1704.
173. University of Chicago. Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE): clinicaltrials. -gov identifier NCT00117572. Available at: http:// clinicaltrials.gov/ct2/show/NCT00117572. Accessed on August 12, 2008.
174. Univerisity of Medicine and Dentistry New Jersey, Dana-Farber Cancer Institute. Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial): clinicaltrials.gov identifier NCT00705068. Available at: http://clinicaltrials. gov/ct2/show/NCT00705068. Accessed on August 12, 2008.
175. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23:705-713.
176. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644-2652.
177. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 pt 2 suppl 93):1-18.
178. Janot F, De Raucourt D, Castaing M, et al; GETTEC and GORTEC. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GETTEC and GORTEC groups [abstract]. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2006;24(18S):5508.
179. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990;8:911-934.
180. Kligerman M. The role of combination radiation and chemotherapy. Cancer. 1960;13(S6):147-157.
181. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol. 2006;24:2612-2617.
182. Adelstein DJ. Recent randomized trials of chemoradiau'on in the management of locally advanced head and neck Cancer. Curr Opin Oncol. 1998;10:213-218.
183. Al-Sarraf M, Pajak TF, Marcial VA, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer. 1987;59:259-265.
184. Crissman JD, Pajak TF, Zarbo RJ, Marcial VA, Al-Sarraf M. Improved response and survival to combined cisplatin and radiation in nonkeratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer. 1987;59:1391-1397.
185. Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group Study 81-17. Cancer. 1990;66:1861-1868.
186. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997;19:567-575.
187. Bourhis J, Amand C, Pignon J-R Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy [abstract]. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004;22(14S). Abstract 5505.
188. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of 8 randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47-56.
189. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol. 1998;16:1310-1317.
190. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
191. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). Head Neck. 2005;27:843-850.
192. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172-183.
193. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007;298:70-82.
194. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996;78:1284-1292.
195. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824-832.
196. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44:1002-1007.
197. Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog Allergy. 1988;45:147-160.
198. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
199. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-1078.
200. Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther. 2006;6:1229-1235.
201. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2659-2665.
202. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-1987.
203. Siu LL. Promising new targeted agents in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2 suppl):S59-S60.
204. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(suppl 3):11-16.
205. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Natl Clin Pract Oncol. 2007;4:156-171.
206. Chacko DC, Hendrickson FR, Fisher A. Definitive irradiation of T1-T4N0 larynx cancer. Cancer. 1983;51:994-1000.
207. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24:3693-3704.
208. Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation? Head Neck. 2004;26:127-135.
209. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004;100:1786-1792.
210. Wang CC. Radiotherapeutic management and results of T1N0, T2N0 carcinoma of the oral tongue: evaluation of boost techniques. Int J Radiat Oncol Biol Phys. 1989;17:287-291.
211. Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. Int J Radiat Oncol Biol Phys. 1990;18:1287-1292.
212. de Braud F, Heilbrun LK, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. Cancer. 1989;64:510-515.
213. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489-501.
214. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004;101:2641-2649.
215. Allal AS, Nicoucar, K, Mach N, Dulguerov P. Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy. Head Neck. 2003;25:833-839; discussion 839-840.
216. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
217. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579-589.
218. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
219. Budach, W, Hehr T, Budach, V, Belka C, Dietz K. A metaanalysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer [serial online]. 2006;6:28.
220. Radiation Oncology Group. A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected patients] for stage HI and IV head and neck carcinoma (clinical trial NCT00265941). Available at: http://clinicaltrials.gov/ct2/shown/NCT00265941. Accessed on August 12, 2008.
221. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
222. Hoffman HT, Porter K, Kamell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116(9 pt 2 suppl 111):1-13.
223. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007;133:1270-1276.
224. List MA, Stracks J, Colangelo L, et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol. 2000;18:877-884.
225. Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634-656.
226. Abendstein H, Nordgren M, Boysen M, et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope. 2005;115:2183-2192.
227. Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch - Head Neck Surg. 2000;126:459-467.